Inhibikase Announces Expansion of Senior Leadership Team
Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief ...
Inhibikase appoints Chris Cabell as president, head of R&D, John Adams as CSO
Inhibikase Therapeutics (IKT) announced the appointment of two pharma industry executives to its senior leadership team. Chris Cabell, M.D., ...
Investing4d
Inhibikase enhances leadership with new appointments
BOSTON - Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a clinical-stage pharmaceutical company with a market capitalization of $201.58 million, has announced the addition of two seasoned executives ...
Business Insider4d
Inhibikase Announces Expansion of Senior Leadership Team
Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief Scientific Officer --- --- Vince Aurentz to join Inhibikase Board of ...
Morningstar4d
Inhibikase Announces Expansion of Senior Leadership Team
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of two ...
Investing4d
Inhibikase enhances leadership with new appointments
BOSTON - Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a clinical-stage pharmaceutical company with a market capitalization of $201.58 million, has announced the addition of two seasoned executives to ...